- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01479998
Novel Treatments to Enhance Smoking Cessation Before Cancer Surgery: Effects on Smoking and Surgical Outcomes
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Participants will be recruited through the Thoracic Oncology Program and the Head and Neck Cancers Program. At the time of their initial surgical consultation, surgeons and their support staff in the Thoracic Oncology Program and Head and Neck Cancers Program will advise all of their patients about the present smoking cessation study as well as the Smoking Cessation Service at Smilow Cancer Hospital/Yale-New Haven Hospital and other resources in the community. Patients who express interest in the study and agree to quit smoking will be met at Smilow/YNHH for an intake appointment by a research assistant. Informed consent will be obtained prior to any other procedures, then during the intake session medical and tobacco use histories and breath carbon monoxide (CO) levels will be obtained from all participants. Study eligibility will be determined in concert with the surgeon and the principal investigator. As agreed upon by the surgeons, if participants meet eligibility criteria, their surgery will be scheduled for approximately 3 weeks after they enter the study.
Eligible participants will be randomized to either: 1) standard care (i.e., 4 counseling sessions and NRT) or 2) standard care + contingency management (i.e., 4 counseling sessions and NRT + 3x/week meetings with positive reinforcers). After this, all subjects will be met by a study therapist for their first counseling session, which is a preparation to quit session. The study counseling protocol will be based on practical counseling, which is a cognitive behavioral evidence based smoking cessation treatment modality (Fiore, Jaén et al. 2008). All participants will be asked to set a quit date within a week after this session. Consistent with the standard practice of the Smoking Cessation Service, all patients will receive pharmacotherapy in conjunction with counseling.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06510
- Yale-New Haven Hospital
-
New Haven, Connecticut, Forente stater, 06615
- Yale Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18 or older,
- smoking 5 or more cigarettes per day, and
- diagnosed with any type of head, neck, or thoracic cancer,
- agreement on a 3-week pre-surgical tobacco intervention by both patient and surgeon.
Exclusion Criteria:
- Unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis, severe alcohol dependence, or dementia,
- history of allergic reactions to adhesives,
- females of childbearing potential who are pregnant, nursing, or not practicing effective contraception.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Standard care and nicotine replacement therapy
standard care is 4 counseling sessions and nicotine replacement therapy
|
standard care plus nicotine replacement therapy
|
Eksperimentell: standard care plus NRT plus contingency management
standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
|
standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
smoking cessation
Tidsramme: up to 3 months
|
up to 3 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- 1104008332
- P50DA009241 (U.S. NIH-stipend/kontrakt)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på standard care
-
Chunrui LiNanjing IASO Biotechnology Co., LtdRekrutteringPlasmacelleleukemi | Residiverende/refraktært myelomatoseKina
-
Bellicum PharmaceuticalsSuspendertHER2-positiv brystkreft | HER2-positiv magekreft | Solid svulst, voksen | HER-2 genamplifikasjon | HER-2 Protein OverekspresjonForente stater
-
Nexcella Inc.Har ikke rekruttert ennåLettkjede (AL) amyloidoseForente stater
-
Second Affiliated Hospital, School of Medicine,...RekrutteringTilbakefallende og refraktær B-celle lymfomKina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...RekrutteringKronisk lymfatisk leukemi | Non-Hodgkin lymfom | Akutt lymfatisk leukemiForente stater
-
Nanjing IASO Biotechnology Co., Ltd.Ruijin HospitalRekrutteringPlasmacelleleukemi | Residiverende/refraktært myelomatoseKina
-
Zhejiang UniversityYake Biotechnology Ltd.Har ikke rekruttert ennåAkutt myeloid leukemiKina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...TilbaketrukketAkutt lymfatisk leukemi | Non-hodgkin lymfomForente stater
-
Hebei Senlang Biotechnology Inc., Ltd.RekrutteringLymfom | Multippelt myelom | Akutt lymfatisk leukemiKina
-
University of California, San FranciscoTilbaketrukketLymfom | Leukemi | Plasmacelledyskrasi